home / stock / calt / calt news


CALT News and Press, Calliditas Therapeutics AB From 11/12/20

Stock Information

Company Name: Calliditas Therapeutics AB
Stock Symbol: CALT
Market: NASDAQ

Menu

CALT CALT Quote CALT Short CALT News CALT Articles CALT Message Board
Get CALT Alerts

News, Short Squeeze, Breakout and More Instantly...

CALT - Calliditas Therapeutics reports Q3 results

Calliditas Therapeutics (CALT): Q3 GAAP EPS of -SEK2.77.Cash of SEK1.4BPress Release For further details see: Calliditas Therapeutics reports Q3 results

CALT - Interim Report Q3, 2020

Interim Report Q3, 2020 Expansion of pipeline and positive phase 3 topline data PR Newswire STOCKHOLM, Nov. 12, 2020 STOCKHOLM , Nov. 12, 2020 /PRNewswire/ -- "On August 13 th , we announced a €19.8m acquisition of a majority stake of 62.7%...

CALT - Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report

Calliditas Therapeutics to host conference call to provide Business Update and 2020 Q3 report PR Newswire STOCKHOLM, Nov. 11, 2020 STOCKHOLM , Nov. 11, 2020 /PRNewswire/ -- On November 12, 2020 , at 07:00 am CET , Calliditas Therapeutics ("Calliditas"...

CALT - Everest Medicines Announces that Licensing Partner Calliditas Therapeutics has Reported Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

SHANGHAI, China, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Everest Medicines (HKEX 1952.HK), a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, ...

CALT - Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial

Calliditas Therapeutics to host conference call on positive topline results from pivotal phase 3 NefIgArd trial PR Newswire STOCKHOLM, Nov. 9, 2020 STOCKHOLM , Nov. 9, 2020 /PRNewswire/ -- On November 8, 2020 , Calliditas announced positive topline result...

CALT - Calliditas' Nefecon successful in late-stage study in kidney disease

Calliditas Therapeutics (CALT) announces positive topline results from Part A of the global Phase 3 clinical trial NefIgArd, investigating the effect of Nefecon versus placebo in patients with primary IgA nephropathy (IgAN). The analysis included 199 patients. The trial met its primary o...

CALT - Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial

Calliditas Announces Positive Topline Results from Pivotal Phase 3 NefIgArd Trial PR Newswire STOCKHOLM, Nov. 9, 2020 STOCKHOLM , Nov. 9, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (OMX Nasdaq: CALTX) (NASDAQ: CALT) ("Calliditas") today announced p...

CALT - Calliditas closes acquisition of a controlling interest in Genkyotex SA

Calliditas closes acquisition of a controlling interest in Genkyotex SA PR Newswire STOCKHOLM, Nov. 3, 2020 STOCKHOLM , Nov. 3, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") (Nasdaq OMX - CALTX; NASDAQ - CALT) today announced the clo...

CALT - Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020

Calliditas Announces Poster and Presentation at ASN Digital Kidney Week 2020 PR Newswire STOCKHOLM, Oct. 19, 2020 STOCKHOLM , Oct. 19, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas") today announced upcoming presentations concerning Ne...

CALT - The 200th patient's last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020

The 200th patient's last visit completed in Part A of NefIgArd supporting topline readout in pivotal Phase 3 trial in Q4, 2020 PR Newswire STOCKHOLM, Oct. 1, 2020 STOCKHOLM , Oct. 1, 2020 /PRNewswire/ -- Calliditas Therapeutics AB (publ) ("Calliditas")...

Previous 10 Next 10